文献速递复苏、休克与脓毒症呼吸衰竭与机械通气重症综合管理与镇静镇痛

意大利伦巴第地区COVID-19疫苗接种与重症监护病房入住及重症肺炎患者结局的关联

Association of COVID-19 Vaccinations With Intensive Care Unit Admissions and Outcome of Critically Ill Patients With COVID-19 Pneumonia in Lombardy, Italy.
PubMed 文献 · JAMA Netw Open · 2022-10-03
一句话结论在Delta变异株为主的时期,接种mRNA或腺病毒载体疫苗与COVID-19肺炎ICU入住风险显著降低相关,但已入ICU的疫苗接种与未接种患者ICU及医院死亡率相似。

这项回顾性队列研究基于意大利伦巴第地区数据,评估COVID-19疫苗接种与ICU入住风险及已入ICU患者结局的关联。研究期间(2021年8月1日至12月15日,Delta变异株为主)共553例COVID-19肺炎患者入住ICU,其中139例(25.1%)已接种疫苗,414例(74.9%)未接种。与未接种者相比,接种mRNA疫苗后120天内ICU入住发生率比(IRR)为0.03(95%CI 0.03-0.04,P<.001),接种腺病毒载体疫苗后超过120天IRR为0.21(95%CI 0.19-0.24,P<.001)。已入ICU的疫苗接种者年龄更大、男性比例更高、合并症更多、入ICU时PaO2/FiO2更高,但ICU及医院死亡率与未接种者相似。

要点

  • 接种mRNA疫苗后120天内,ICU入住发生率比(IRR)为0.03(95%CI 0.03-0.04,P<.001),显著低于未接种者。
  • 接种腺病毒载体疫苗后超过120天,ICU入住IRR为0.21(95%CI 0.19-0.24,P<.001),仍显著低于未接种者。
  • 已入ICU的疫苗接种者较未接种者年龄更大(中位72岁 vs 60岁,P<.001)、男性更多(79.1% vs 60.9%,P<.001)、合并症更多(中位2 vs 0,P<.001)。
  • 已入ICU的疫苗接种者入ICU时PaO2/FiO2更高(中位138 vs 120 mm Hg,P=.007),但ICU及医院死亡率与未接种者相似。
  • 与ICU及医院死亡率相关的因素包括较高年龄、病前心脏病、入ICU时较低PaO2/FiO2,女性仅与ICU死亡率相关。

适用人群与场景

  • 意大利伦巴第地区2021年8月1日至12月15日(Delta变异株为主)期间所有连续入住ICU的COVID-19肺炎患者。
  • 疫苗接种状态分为未接种、mRNA疫苗(BNT162b2或mRNA-1273)、腺病毒载体疫苗(ChAdOx1-S或Ad26.COV2)。

研究设计与关键结果

  • 研究类型:回顾性队列研究,基于意大利伦巴第地区数据集,报告每日疫苗接种数量及2021年8月1日至12月15日所有连续入住ICU的患者数据。
  • 研究人群:伦巴第地区10 107 674名居民,中位[IQR]年龄48[28-64]岁,5 154 914名(51.0%)为女性;7 863 417人接种疫苗(中位[IQR]年龄53[33-68]岁;4 010 343名[51.4%]女性),其中6 251 417人(79.5%)接种mRNA疫苗,550 439人(7.0%)接种腺病毒载体疫苗,1 061 561人(13.5%)接种混合疫苗,4 497 875人(57.2%)接种加强针。
  • 主要终点:与未接种者相比,接种mRNA疫苗后120天内ICU入住IRR为0.03(95%CI 0.03-0.04;P<.001);接种腺病毒载体疫苗后超过120天IRR为0.21(95%CI 0.19-0.24;P<.001)。
  • ICU入住患者:研究期间共553例COVID-19肺炎患者入住ICU,其中139例(25.1%)已接种疫苗,414例(74.9%)未接种。
  • 疫苗接种者与未接种者比较:年龄更大(中位[IQR]72[66-76]岁 vs 60[51-69]岁;P<.001),男性为主(110例[79.1%] vs 252例[60.9%];P<.001),合并症更多(中位[IQR]2[1-3] vs 0[0-1];P<.001),入ICU时PaO2/FiO2更高(中位[IQR]138[100-180] mm Hg vs 120[90-158] mm Hg;P=.007)。
  • 与ICU及医院死亡率相关的因素:较高年龄、病前心脏病、入ICU时较低PaO2/FiO2,以及女性(仅与ICU死亡率相关)。
  • ICU及医院死亡率在疫苗接种者与未接种者之间相似。

证据类型、等级与局限

  • 证据类型:回顾性队列研究。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 作者认为,这些发现提示接种疫苗人群中发生需要ICU入住的COVID-19相关严重急性呼吸衰竭的风险大幅降低。
  • 已入ICU的COVID-19肺炎患者中,疫苗接种状态与ICU及医院死亡率无关;与死亡率相关的因素为较高年龄、病前心脏病、入ICU时较低PaO2/FiO2,女性仅与ICU死亡率相关。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

IMPORTANCE: Data on the association of COVID-19 vaccination with intensive care unit (ICU) admission and outcomes of patients with SARS-CoV-2-related pneumonia are scarce.

OBJECTIVE: To evaluate whether COVID-19 vaccination is associated with preventing ICU admission for COVID-19 pneumonia and to compare baseline characteristics and outcomes of vaccinated and unvaccinated patients admitted to an ICU.

DESIGN, SETTING, AND PARTICIPANTS: This retrospective cohort study on regional data sets reports: (1) daily number of administered vaccines and (2) data of all consecutive patients admitted to an ICU in Lombardy, Italy, from August 1 to December 15, 2021 (Delta variant predominant). Vaccinated patients received either mRNA vaccines (BNT162b2 or mRNA-1273) or adenoviral vector vaccines (ChAdOx1-S or Ad26.COV2). Incident rate ratios (IRRs) were computed from August 1, 2021, to January 31, 2022; ICU and baseline characteristics and outcomes of vaccinated and unvaccinated patients admitted to an ICU were analyzed from August 1 to December 15, 2021.

EXPOSURES: COVID-19 vaccination status (no vaccination, mRNA vaccine, adenoviral vector vaccine).

MAIN OUTCOMES AND MEASURES: The incidence IRR of ICU admission was evaluated, comparing vaccinated people with unvaccinated, adjusted for age and sex. The baseline characteristics at ICU admission of vaccinated and unvaccinated patients were investigated. The association between vaccination status at ICU admission and mortality at ICU and hospital discharge were also studied, adjusting for possible confounders.

RESULTS: Among the 10 107 674 inhabitants of Lombardy, Italy, at the time of this study, the median [IQR] age was 48 [28-64] years and 5 154 914 (51.0%) were female. Of the 7 863 417 individuals who were vaccinated (median [IQR] age: 53 [33-68] years; 4 010 343 [51.4%] female), 6 251 417 (79.5%) received an mRNA vaccine, 550 439 (7.0%) received an adenoviral vector vaccine, and 1 061 561 (13.5%) received a mix of vaccines and 4 497 875 (57.2%) were boosted. Compared with unvaccinated people, IRR of individuals who received an mRNA vaccine within 120 days from the last dose was 0.03 (95% CI, 0.03-0.04; P < .001), whereas IRR of individuals who received an adenoviral vector vaccine after 120 days was 0.21 (95% CI, 0.19-0.24; P < .001). There were 553 patients admitted to an ICU for COVID-19 pneumonia during the study period: 139 patients (25.1%) were vaccinated and 414 (74.9%) were unvaccinated. Compared with unvaccinated patients, vaccinated patients were older (median [IQR]: 72 [66-76] vs 60 [51-69] years; P < .001), primarily male individuals (110 patients [79.1%] vs 252 patients [60.9%]; P < .001), with more comorbidities (median [IQR]: 2 [1-3] vs 0 [0-1] comorbidities; P < .001) and had higher ratio of arterial partial pressure of oxygen (Pao2) and fraction of inspiratory oxygen (FiO2) at ICU admission (median [IQR]: 138 [100-180] vs 120 [90-158] mm Hg; P = .007). Factors associated with ICU and hospital mortality were higher age, premorbid heart disease, lower Pao2/FiO2 at ICU admission, and female sex (this factor only for ICU mortality). ICU and hospital mortality were similar between vaccinated and unvaccinated patients.

CONCLUSIONS AND RELEVANCE: In this cohort study, mRNA and adenoviral vector vaccines were associated with significantly lower risk of ICU admission for COVID-19 pneumonia. ICU and hospital mortality were not associated with vaccinated status. These findings suggest a substantial reduction of the risk of developing COVID-19-related severe acute respiratory failure requiring ICU admission among vaccinated people.

来源:JAMA Netw Open,查看原文。版权归原作者所有。

参考来源

  1. Grasselli G, Zanella A, Carlesso E, et al. Association of COVID-19 Vaccinations With Intensive Care Unit Admissions and Outcome of Critically Ill Patients With COVID-19 Pneumonia in Lombardy, Italy. JAMA Netw Open. 2022. PMID: 36301541. doi:10.1001/jamanetworkopen.2022.38871

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。